Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves injectable monoclonal antibody for severe asthma

The FDA has approved mepolizumab (GlaxoSmithKline’s Nucala), which reduces severe asthma attacks by cutting the levels of blood eosinophils (micrograph pictured) – a type of white blood cell that contributes to the development of asthma

Source: Biophoto Associates / Science Photo Library

Mepolizumab can cut severe asthma attacks by reducing the levels of eosinophils (pictured), a white blood cell that is linked to asthma 

The US Food and Drug Administration (FDA) has approved mepolizumab (GlaxoSmithKline’s Nucala), a humanised interleukin-5 antagonist monoclonal antibody, for use with other drugs to treat asthma in patients aged 12 years and over. 

It is approved for patients who have a history of severe asthma attacks, or exacerbations, despite receiving their current asthma medications, the FDA says. 

Mepolizumab — produced by recombinant DNA technology in Chinese hamster ovary cells — reduces severe asthma attacks by cutting the levels of blood eosinophils, a type of white blood cell that contributes to the development of asthma. 

Patients receive Nucala once every four weeks by subcutaneous injection into the upper arm, thigh or abdomen. 

The drug’s safety and efficacy were established in three double-blind, randomised, placebo-controlled trials in patients with severe asthma on currently available therapies. 

Researchers administered either Nucala or a placebo to patients every four weeks as an additional asthma treatment. Compared with the placebo, patients with severe asthma receiving Nucala had fewer exacerbations requiring hospitalisation and/or emergency department visits, and a longer time to the first exacerbation. 

Patients receiving Nucala also saw greater reductions in their daily maintenance oral corticosteroid dose, while maintaining asthma control, although the medication did not result in a significant improvement in lung function. 

Common side effects include headache, injection site reactions, back pain and fatigue. Hypersensitivity reactions can occur within hours or days of being treated with the agent, and herpes zoster infections have occurred, the FDA says.

In September 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for mepolizumab, recommending the granting of a marketing authorisation for the drug for the treatment of severe refractory eosinophilic asthma.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200012

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The FDA has approved mepolizumab (GlaxoSmithKline’s Nucala), which reduces severe asthma attacks by cutting the levels of blood eosinophils (micrograph pictured) – a type of white blood cell that contributes to the development of asthma

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.